Acadia Pharmaceuticals (ACAD) Non-Current Assets (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Non-Current Assets of $509.2 million for Q1 2026, up 94.79% year-over-year from $261.4 million in Q1 2025, and up 1.42% quarter-over-quarter from $502.1 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Non-Current Assets (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $509.2 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 94.79% year-over-year to $509.2 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 73.03% YoY), while the FY2025 annual figure was $502.1 million, up 101.29% from the prior year.
- Non-Current Assets for Q1 2026 stood at $509.2 million, up from $502.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $509.2 million in Q1 2026, with the low at $79.9 million in Q4 2022.
- The 5-year median for Non-Current Assets is $179.8 million (2024), against an average of $205.1 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets retreated 2.95% in 2022, then soared 101.29% in 2025.
- Acadia Pharmaceuticals' Non-Current Assets stood at $79.9 million in 2022, then jumped by 66.3% to $132.8 million in 2023, then soared by 87.79% to $249.4 million in 2024, then jumped by 101.29% to $502.1 million in 2025, then rose by 1.42% to $509.2 million in 2026.
- Business Quant data shows ACAD's Non-Current Assets at $509.2 million in Q1 2026, $502.1 million in Q4 2025, and $254.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 518.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 518.36 Mn |
| Mar 31, 2026 | 509.21 Mn |
| Dec 31, 2025 | 502.08 Mn |
| Sep 30, 2025 | 254.35 Mn |
| Jun 30, 2025 | 265.00 Mn |
| Mar 31, 2025 | 261.42 Mn |
| Dec 31, 2024 | 249.44 Mn |
| Sep 30, 2024 | 188.58 Mn |
| Jun 30, 2024 | 185.18 Mn |
| Mar 31, 2024 | 179.81 Mn |
| Dec 31, 2023 | 132.83 Mn |
| Sep 30, 2023 | 133.37 Mn |
| Jun 30, 2023 | 150.14 Mn |
| Mar 31, 2023 | 152.46 Mn |
| Dec 31, 2022 | 79.88 Mn |
| Sep 30, 2022 | 80.94 Mn |
| Jun 30, 2022 | 80.25 Mn |
| Mar 31, 2022 | 82.03 Mn |
| Dec 31, 2021 | 82.30 Mn |
| Sep 30, 2021 | 76.76 Mn |